ES2186674T3 - Comprimidos de liberacion sostenida que contienen niacina y estuches. - Google Patents

Comprimidos de liberacion sostenida que contienen niacina y estuches.

Info

Publication number
ES2186674T3
ES2186674T3 ES93401681T ES93401681T ES2186674T3 ES 2186674 T3 ES2186674 T3 ES 2186674T3 ES 93401681 T ES93401681 T ES 93401681T ES 93401681 T ES93401681 T ES 93401681T ES 2186674 T3 ES2186674 T3 ES 2186674T3
Authority
ES
Spain
Prior art keywords
kids
tablets
cases
sustained release
release containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93401681T
Other languages
English (en)
Inventor
Victoria A O'neill
Kenneth L Evenstad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kos Pharmaceuticals Inc
Original Assignee
Kos Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25421462&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2186674(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kos Pharmaceuticals Inc filed Critical Kos Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2186674T3 publication Critical patent/ES2186674T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Physical Water Treatments (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA INVENCION PRESENTA UN METODO TERAPEUTICO PARA EL TRATAMIENTO DE LA HIPERLIPIDEMIA QUE CONSISTE EN ADMINISTRAR A UN PACIENTE HUMANO UNA SOLA DOSIS DIARIA DE UN TIPO DE DOSIS DE LIBERACION PROLONGADA DE NIACINA, DE TAL MODO QUE SE ELIMINA DE MANERA EFECTIVA LA SINTESIS NOCTURNA DEL COLESTEROL.
ES93401681T 1992-06-29 1993-06-29 Comprimidos de liberacion sostenida que contienen niacina y estuches. Expired - Lifetime ES2186674T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/905,785 US5268181A (en) 1989-04-13 1992-06-29 Method of using niacin to control nocturnal cholesterol synthesis

Publications (1)

Publication Number Publication Date
ES2186674T3 true ES2186674T3 (es) 2003-05-16

Family

ID=25421462

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93401681T Expired - Lifetime ES2186674T3 (es) 1992-06-29 1993-06-29 Comprimidos de liberacion sostenida que contienen niacina y estuches.

Country Status (7)

Country Link
US (1) US5268181A (es)
EP (3) EP1310253A1 (es)
AT (1) ATE227128T1 (es)
DE (1) DE69332463T2 (es)
DK (1) DK0577504T3 (es)
ES (1) ES2186674T3 (es)
PT (1) PT577504E (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721221A (en) * 1991-03-08 1998-02-24 Regents Of The University Of Minnesota Lowering blood cholesterol levels using water soluble cellulose ethers
DE4329794C2 (de) * 1993-09-03 1997-09-18 Gruenenthal Gmbh Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6746691B2 (en) * 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6676967B1 (en) * 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6406715B1 (en) * 1993-09-20 2002-06-18 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
EP0643965B1 (en) * 1993-09-20 2013-05-08 Abbott Laboratories Nicotinic acid compositions for treating hyperlipidemia
US20060263428A1 (en) * 1993-09-20 2006-11-23 Eugenio Cefali Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics
US20080045573A1 (en) * 1993-09-20 2008-02-21 Bova David J Methods and Sustained Release Nicotinic Acid Compositions for Treating Hyperlipidemia
AU5787996A (en) * 1995-04-19 1996-11-07 Lipoprotein Technologies, Inc. Compositions, kits, and methods for administration of antilipemic and anti-platelet aggregation drugs
EP1181954A3 (en) * 1995-06-07 2002-08-21 Pfizer Inc. Biphenyl-2-carboxylic acid-tetrahydro-isoquinolin-6-yl amide derivatives, their preparation and use as inhibitors of microsomal triglyceride transfer protein and/or apolipoprotein B (ApoB) secretion
US7179486B1 (en) * 1997-04-01 2007-02-20 Nostrum Pharmaceuticals, Inc. Process for preparing sustained release tablets
US20010006644A1 (en) 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
US6469035B1 (en) * 1997-07-31 2002-10-22 Eugenio A. Cefali Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid
EP1017390B1 (en) * 1997-07-31 2007-04-18 Kos Life Sciences, Inc. Coated tablet comprising nicotinic acid or a compound metabolized to nicotinic acid in an extended release form, and a coating containing an hmg-coa reductase inhibitor in an immediate release form
AR030557A1 (es) * 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
UA77660C2 (en) 2000-10-03 2007-01-15 Compositions and methods for reducing plasma lipoprotein a level in human
US7052706B2 (en) * 2001-06-08 2006-05-30 Nostrum Pharmaceuticals, Inc. Control release formulation containing a hydrophobic material as the sustained release agent
EP1811996A1 (en) * 2004-11-05 2007-08-01 Arena Pharmaceuticals, Inc. Compositions for treating flushing and lipid-associated disorders comprising niacin receptor partial agonists
US20080096979A1 (en) * 2004-11-08 2008-04-24 Rubicon Research Pvt. Ltd. Aqueous Pharmaceutical Coating
FR2878748B1 (fr) * 2004-12-07 2007-03-09 Arrow Generiques Soc Par Actio Formule de comprimes permettant une liberation prolongee d'indapamide apres administration par voie orale et procede de preparation
AU2006214286A1 (en) * 2005-02-18 2006-08-24 Arena Pharmaceuticals, Inc. Methods and compositions for the treatment of lipid-associated disorders
US20070053930A1 (en) * 2005-09-07 2007-03-08 Bebaas, Inc. Combination therapy for treatment of high cholesterol
CA2569776A1 (en) * 2006-02-17 2007-08-17 Kos Life Sciences, Inc. Low flush niacin formulation
WO2008100249A1 (en) * 2007-02-13 2008-08-21 Kos Life Sciences, Inc. Low flush niacin formulation
CN101686674A (zh) * 2007-03-01 2010-03-31 康考斯保健科学有限责任公司 肌醇烟酸酯的异构体及其用途
TW200901959A (en) 2007-03-09 2009-01-16 Indigene Pharmaceuticals Inc Combination of metformin R-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
KR100836960B1 (ko) 2007-09-07 2008-06-10 주식회사 서울제약 새로운 나이아신 제어방출형 제제
US20110123575A1 (en) * 2008-06-02 2011-05-26 Dr. Reddy's Laboratories Ltd. Modified release niacin formulations
WO2010010579A1 (en) * 2008-07-19 2010-01-28 Lupin Limited Multiple unit dosage form of niacin
ES2660118T3 (es) 2011-10-05 2018-03-20 Jeffrey M. Golini Composición de colina
US20140113939A1 (en) * 2012-10-22 2014-04-24 Abbott Laboratories Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065143A (en) * 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
JPS5031022A (es) * 1973-05-29 1975-03-27
US4166902A (en) * 1974-10-14 1979-09-04 Paolo Ferruti High polymers containing nicotinic acid, process for their preparation and their use
US4568547A (en) * 1979-08-30 1986-02-04 Herschler R J Solid pharmaceutical compositions comprising MSM and their production
FR2471186A1 (fr) * 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4457907A (en) * 1982-08-05 1984-07-03 Clear Lake Development Group Composition and method for protecting a therapeutic drug
FR2535202B1 (fr) * 1982-11-03 1985-08-09 Fabre Sa Pierre Comprimes de theophylline a liberation controlee et leur procede de fabrication
US4749575A (en) * 1983-10-03 1988-06-07 Bio-Dar Ltd. Microencapsulated medicament in sweet matrix
US4680323A (en) * 1983-12-01 1987-07-14 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration
US4704285A (en) * 1985-11-18 1987-11-03 The Dow Chemical Company Sustained release compositions comprising hydroxypropyl cellulose ethers
NL8600050A (nl) * 1986-01-13 1987-08-03 Sanico Nv Farmaceutisch preparaat met vertraagde afgifte van het werkzame bestanddeel en werkwijze voor de bereiding er van.
US4756911A (en) * 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
US4795642A (en) * 1986-05-01 1989-01-03 Pharmacaps, Inc. Gelatin-encapsulated controlled-release composition
US4708834A (en) * 1986-05-01 1987-11-24 Pharmacaps, Inc. Preparation of gelatin-encapsulated controlled release composition
US4752479A (en) * 1986-05-27 1988-06-21 Ciba-Geigy Corporaton Multi vitamin and mineral dietary supplement with controlled release bioavailable iron
US5110940A (en) * 1987-02-25 1992-05-05 Bristol-Myers Company Antihypercholesterolemic tetrazole compounds
US4950689A (en) * 1987-03-31 1990-08-21 Yang Robert K Pectin delivery system
JPS63310827A (ja) * 1987-06-15 1988-12-19 Sanwa Kagaku Kenkyusho Co Ltd ニコチン酸誘導体を主剤とする徐放性製剤
US5023245A (en) * 1987-11-10 1991-06-11 Hauser-Kuhrts, Inc. Improved niacin formulation
US4911917A (en) * 1988-06-28 1990-03-27 Hauser-Kuhrts, Inc. Cholesterol-lowering combination comopsitions of magnesium salt and niacin
US4965252A (en) * 1988-06-28 1990-10-23 Hauser-Kuhrts, Inc. Cholesterol-lowering combination compositions of guar gum and niacin
US5116610A (en) * 1987-12-29 1992-05-26 The Procter & Gamble Company Compositions for treating hypercholesterolemia
US5030653A (en) * 1988-03-30 1991-07-09 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic compounds and compositions
US5049696A (en) * 1988-04-11 1991-09-17 Merck & Co., Inc. Antihypercholesterolemic compounds
US5096714A (en) * 1988-06-28 1992-03-17 Hauser-Kuhrts, Inc. Prolonged release drug tablet formulations
US5034528A (en) * 1988-07-27 1991-07-23 North Carolina Central University Compositions for the control of hyperlipidemia
US5011947A (en) * 1988-08-25 1991-04-30 Bristol-Myers Antihypercholesterolemic alkylene compounds
US5110817A (en) * 1988-10-21 1992-05-05 Beyer Jr Karl H Method for controlling and/or lowering serum triglyceride and/or cholesterol levels in mammals
US4920123A (en) * 1988-10-21 1990-04-24 Beyer Jr Karl H Method for controlling and/or lowering serum triglyceride and/or cholesterol levels in mammals
US4920115A (en) * 1988-12-28 1990-04-24 Virginia Commonwealth University Method of lowering LDL cholesterol in blood
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US5002774A (en) * 1989-06-08 1991-03-26 Erbamont, Inc. Sustained release pharmaceutical tablet
US5010105A (en) * 1989-06-09 1991-04-23 Merck & Co., Inc. Antihypercholesterolemic compounds

Also Published As

Publication number Publication date
PT577504E (pt) 2003-03-31
DE69332463D1 (de) 2002-12-12
DE69332463T2 (de) 2003-07-10
EP1310253A1 (en) 2003-05-14
US5268181A (en) 1993-12-07
EP1688143A3 (en) 2009-11-11
EP1688143A2 (en) 2006-08-09
EP0577504A1 (en) 1994-01-05
EP0577504B1 (en) 2002-11-06
DK0577504T3 (da) 2003-03-17
ATE227128T1 (de) 2002-11-15

Similar Documents

Publication Publication Date Title
ATE227128T1 (de) Niacin enthaltende tabletten und sätze mit verzögerter wirkstoffabgabe
EP0647133A4 (en) COMPOSITIONS AND METHODS FOR IMPROVED DRUG DELIVERY.
FI921383A7 (fi) Lapsille turvallinen yksikköannospakkaus ja erillinen lääkepakkaus
NO306235B1 (no) Anvendelse av et legemiddel for behandling av artritt
FI940787A7 (fi) Annostusmuoto lääkkeen annostelemiseksi lyhyessä ajanjaksossa
EP0581226A3 (en) Light-curing reactor and small light irradiation device for dental use.
NO933239D0 (no) Bioeroderbar innretning for administering av aktive ingredienser
DK0494972T3 (da) Brusedosisform samt fremgangsmåde til administration heraf
FI945198L (fi) Farmaseuttiset ja muut annosmuodot
WO1994027589A3 (en) Antidepressant dosage form
GB9200417D0 (en) Cytotoxic drug therapy
FI934132A7 (fi) Lääkkeen annostelulaite
PT93490A (pt) Sistema de libertacao de medicamentos administratos intra-oralmente
NO910080D0 (no) Svelgbare doseringsenheter omfattende kolloidalt vismut-subsitrat.
GB2270262B (en) Wheeliebin freshener and disinfector
NO179504C (no) Legemiddel i form av en tablett inneholdende diritromycin
FI950725L (fi) Trisyklisen yhdisteen käyttö muistin ja tajunnan häiriöiden hoitoon tarkoitettujen lääkevalmisteiden valmistukseen
ITMI922885A1 (it) Composizioni farmaceutiche a rilascio controllato contenenti nicergolina
GB9302004D0 (en) A device for protacted release of active substances,perfumes and similar volatile substances
DE68909555D1 (de) Pyridylketoximether-verbindung und diese enthaltende pharmazeutische zusammensetzung.
HUP9801236A3 (en) Use of forskolin or extracts containing it in the manufacture of a medicament for the treatment of alcohol addiction
FI930097A7 (fi) Annostusmuoto lääkeaineen antamiseksi vuorokausiterapian toteuttamista varten
GB9508938D0 (en) Medication dosage reminder device
EG19885A (en) Medicament for the treatment of hyperlipidaemia and/or atherosolerosis
ZA925931B (en) Medicinal treatment